Welcome to our dedicated page for Cyclerion Therapeutics news (Ticker: CYCN), a resource for investors and traders seeking the latest updates and insights on Cyclerion Therapeutics stock.
Cyclerion Therapeutics reports developments as a clinical-stage biopharmaceutical company focused on neuropsychiatric diseases. Its recurring news centers on CYC-126, a lead program for treatment-resistant depression, including FDA interactions, clinical development planning, advisory-board activity, and work on an anesthesia-enabled therapeutic approach.
Company updates also cover licensing and collaboration agreements, including technology rights for neuropsychiatric disorders and closed-loop anesthetic delivery, as well as the ongoing management of legacy soluble guanylate cyclase, or sGC, assets such as praliciguat and olinciguat. Governance changes, board composition, shareholder matters, expense management, and capital-structure disclosures are recurring themes in Cyclerion’s public-company communications.
Cyclerion Therapeutics (Nasdaq: CYCN) announced an upcoming webcast investor event on July 9, 2020, from 8:15 a.m. to 9:30 a.m. Eastern Time, focusing on IW-6463, a CNS-penetrant sGC stimulator for serious CNS diseases. The company has completed dosing in the IW-6463 clinical study, with topline data expected in late summer 2020. The webcast will cover the therapeutic potential of the nitric oxide/sGC system, preclinical and Phase 1 study data, and future directions for CNS therapies. The event will be available on the Cyclerion website and archived for 21 days.